News

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster manufacturing, shaking up the $150-bn obesity market ...
Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...
Pipeline operator Williams will seek to build two natural-gas supply lines to New York following talks between President Trump and Gov. Kathy Hochul. GameStop makes its first bitcoin buy. Here's why ...
Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle ...
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...
The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...
GLP-1 drugs like Ozempic are revolutionizing diabetes care. But they’re also making users less likely to drink alcohol. That ...
HHS Secretary RFK Jr. removes the COVID-19 vaccine recommendation for healthy kids and pregnant women—the latest in a string of changes to vaccine policies; judge issues an order to halt HHS’ ...
Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...
Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...
Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.